Top Buy
| Security | Buy | Sell | Buy (1M) | Sell (1M) | Price | Target price ▼ | Potential |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 36 | 1 | 3 | 0 | €895.60 | €958.32 | 7.003% |
| Eli Lilly Corp. | 49 | 0 | 6 | 0 | €747.90 | €776.16 | 3.779% |
| Medpace Holdings Inc | 11 | 0 | 2 | 0 | €357.60 | €419.64 | 17.348% |
| Vertex Pharmaceuticals Inc. | 47 | 2 | 7 | 0 | €411.25 | €416.05 | 1.167% |
| Amgen Inc. | 25 | 0 | 4 | 0 | €273.55 | €296.16 | 8.264% |
| Biogen Inc. | 49 | 1 | 8 | 0 | €194.30 | €293.22 | 50.913% |
| United Therapeutics | 19 | 0 | 4 | 0 | €244.10 | €287.40 | 17.739% |
| Charles River Labs Intl | 10 | 0 | 1 | 0 | €196.20 | €248.57 | 26.692% |
| Alnylam Pharmace. | 36 | 0 | 2 | 0 | €137.90 | €236.30 | 71.355% |
| Zoetis Inc. A | 23 | 1 | 3 | 0 | €157.72 | €200.06 | 26.843% |
| Repligen Corp. | 13 | 0 | 1 | 0 | €144.35 | €184.76 | 27.994% |
| Krystal Biotech | 17 | 0 | 1 | 0 | €146.35 | €179.60 | 22.716% |
| AbbVie Inc. | 22 | 0 | 4 | 0 | €143.82 | €175.11 | 21.757% |
| Neurocrine Bioscience | 31 | 0 | 8 | 0 | €123.00 | €140.60 | 14.312% |
| Merck & Co. Inc. | 28 | 1 | 0 | 0 | €116.60 | €124.92 | 7.137% |
| Abbott Laboratories | 17 | 0 | 1 | 0 | €93.62 | €116.71 | 24.667% |
| Aveo Pharmaceuticals Inc. | 1 | 0 | 0 | 0 | €13.85 | €100.00 | 622.022% |
| Axsome Therapeutics Inc | 2 | 0 | 0 | 0 | €68.88 | €100.00 | 45.180% |
| Viking Therapeutics Inc | 5 | 0 | 3 | 0 | €58.84 | €100.00 | 69.952% |
| Ultragenyx Pharmaceutical Inc. | 17 | 1 | 1 | 0 | €35.60 | €84.74 | 138.045% |
| Cytokinetics Inc. | 31 | 2 | 9 | 1 | €45.00 | €83.06 | 84.572% |
| Intra-Cellular Therapies Inc. | 25 | 0 | 2 | 0 | €60.00 | €79.55 | 32.591% |
| Incyte Corp. | 12 | 2 | 2 | 0 | €52.16 | €78.42 | 50.350% |
| Apellis Pharmaceuticals | 3 | 0 | 0 | 0 | €37.34 | €70.00 | 87.467% |
| XOMA Corp. | 6 | 0 | 2 | 0 | €22.40 | €68.78 | 207.050% |